05:01 PM EST, 01/28/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) and Helsinn Healthcare after trade Tuesday said they expanded their partnership with a new exclusive agreement for Onicit intravenous (palonosetron) in Mexico, Brazil, and other Latin American countries.

Knight will have the exclusive rights to distribute, promote, market, and sell Onicit in these areas, starting after a transition from Helsinn's previous licensee.

Onicit is a second-generation 5-HT3 receptor antagonist. A single dose before chemotherapy provides protection from nausea and vomiting for days 1 to 5, covering both the acute and delayed phases after treatment. It is sold under the Aloxi brand name in Canada.

The new agreement builds on the companies' existing relationship, which includes a similar agreement for Akynzeo oral/IV and Aloxi oral/IV in various countries, including Canada, Brazil, Argentina, Uruguay, and Paraguay, made in May 2022.

Knight shares closed up $0.05 to $5.75 on the Toronto Stock Exchange.